Alectos Therapeutics discovers novel treatments to block the underlying progression of neurodegenerative diseases. Alectos identifies and develops innovative strategies to address complex neurological conditions, including Alzheimer’s disease and Parkinson’s disease.
The Alectos pipeline is focused on creating new therapeutics to treat patients living with these disorders. Our GBA2 program is a disease-modifying approach to correct lysosomal dysfunction in neurodegenerative diseases, including Parkinson’s disease. This program has recently been partnered with Biogen. Our OGA program is a strategy to prevent the accumulation and spread of toxic protein aggregates in the brain. Alectos partnered with Merck to pioneer the development of the first clinical OGA inhibitor. Alectos has repatriated this program and we are applying our deep knowledge and IP to advance novel OGA inhibitors as treatments for Alzheimer’s disease, frontotemporal dementia, and ischemic stroke. We welcome partnership inquiries regarding our OGA program and our advanced preclinical development candidates.